Details

Autor(en) / Beteiligte

• Yao, Zhixian
• Zheng, Zhong
• Zheng, Xinyi
• Wu, Hantao
• Zhao, Weiguang
• Mu, Xingyu
• Sun, Feng
• Wu, Ke
• Zheng, Junhua
• Xu, Qiongming
• Qiongming Xu

Titel

Comprehensive Characterization of Metabolism-Associated Subtypes of Renal Cell Carcinoma to Aid Clinical Therapy

Ist Teil von

• Oxidative medicine and cellular longevity, 2022, Vol.2022, p.9039732-27

Ort / Verlag

United States: Hindawi

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Renal cell carcinoma (RCC) is a disease characterized by excessive administration complexity because it exhibits extraordinary nonuniformity among distinct molecular subtypes. We herein intended to delineate the metabolic aspects of clear cell RCC (ccRCC) in terms of the gene expression profile. Recent studies have revealed that metabolic variations within tumors are related to the responsiveness to immune checkpoint inhibitor (ICI) therapy and patient prognosis. We used 100 previously reported metabolic (MTB) pathways to quantify the metabolic landscape of the 729 ccRCC patients. Three MTB subtypes were established, and the MTB scores were calculated using principal component analysis (PCA). The high MTB score group had better overall survival (OS) and was associated with higher expression of immune-checkpoint and immune-activity signatures. The opposite was true of the low MTB score group, which may explain the poor prognosis of these patients. Three ICI-treated cohorts or tyrosine kinase inhibitor (TKI) treated cohort proved that patients with higher MTB scores exhibited notable therapeutic benefits and clinical gains. This research explained that the MTB score could be applied as a powerful prognostic indicator and predictive of ICI or TKI therapy. Assessing the MTB scores in a more extended group will facilitate our perception of tumor metabolism and provide guidance for studies on targeted approaches for ccRCC patients.